Limits...
The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Yang L, Zhao J, Zhou G, Wang Y, Li L, Yuan H, Nan X, Guan L, Pei X - Neural Regen Res (2012)

Bottom Line: Hematoxylin-eosin staining verified that intracranial tumors were gliomas.Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model.Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, the 263 Hospital, Beijing 101149, China ; Department of Neurology, South West Hospital, the Third Military Medical University of Chinese PLA, Chongqing 400038, China.

ABSTRACT
The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9L(LUC) glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9L(LUC)/F344 rats, and tumor regression was found in some 9L(LUC)/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

No MeSH data available.


Related in: MedlinePlus

Photon counts of 9L/F344 and 9L/Wistar rats implanted with 9LLUC cells at day 7 to day 21.There were no obvious differences among groups at day 7 after cell implantation. Tumors disappeared gradually in 9L/Wistar rats receiving 105 9LLUC cells, while a significant increase was observed between 9L/Wistar rats receiving 106 9LLUC cells and 9L/F344 rats receiving 105 9LLUC cells at day 14. Compared with 9L/Wistar rats, the glioma in 9L/F344 rats continued to develop. The data are expressed as mean ± SEM and were analyzed with Student's t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4308791&req=5

Figure 3: Photon counts of 9L/F344 and 9L/Wistar rats implanted with 9LLUC cells at day 7 to day 21.There were no obvious differences among groups at day 7 after cell implantation. Tumors disappeared gradually in 9L/Wistar rats receiving 105 9LLUC cells, while a significant increase was observed between 9L/Wistar rats receiving 106 9LLUC cells and 9L/F344 rats receiving 105 9LLUC cells at day 14. Compared with 9L/Wistar rats, the glioma in 9L/F344 rats continued to develop. The data are expressed as mean ± SEM and were analyzed with Student's t-test.

Mentions: 9LLUC glioma cells were injected into the cranium of Wistar or F344 rats to monitor tumor growth. Tumor growth was measured at the beginning on day 0 and weekly thereafter using bioluminescence imaging. By day 7, all animals showed successful tumor development following bioluminescence imaging. Tumor growth after intracranial injection of 9LLUC cells at varying doses into the right caudate nucleus of Wistar or F344 rats is shown in Figure 2. All 9LLUC/F344 rats yielded tumors with an injection of 105 cells (Figures 2A–D); in contrast, Wistar rats injected with 106 cells showed successful tumor development (Figures 2I-L), yet Wistar rats injected with 105 cells developed tumors only on day 7 and regressed thereafter (Figures 2E-H). Compared with 9L/Fischer rats, Wistar rats implanted with 9L glioma cells (106) showed a significant (P < 0.01) increase in photon counts at day 7, however, there was no difference in photon counts between 9L/Fischer rats and Wistar rats at day 21 (P > 0.05; Figure 3).


The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Yang L, Zhao J, Zhou G, Wang Y, Li L, Yuan H, Nan X, Guan L, Pei X - Neural Regen Res (2012)

Photon counts of 9L/F344 and 9L/Wistar rats implanted with 9LLUC cells at day 7 to day 21.There were no obvious differences among groups at day 7 after cell implantation. Tumors disappeared gradually in 9L/Wistar rats receiving 105 9LLUC cells, while a significant increase was observed between 9L/Wistar rats receiving 106 9LLUC cells and 9L/F344 rats receiving 105 9LLUC cells at day 14. Compared with 9L/Wistar rats, the glioma in 9L/F344 rats continued to develop. The data are expressed as mean ± SEM and were analyzed with Student's t-test.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4308791&req=5

Figure 3: Photon counts of 9L/F344 and 9L/Wistar rats implanted with 9LLUC cells at day 7 to day 21.There were no obvious differences among groups at day 7 after cell implantation. Tumors disappeared gradually in 9L/Wistar rats receiving 105 9LLUC cells, while a significant increase was observed between 9L/Wistar rats receiving 106 9LLUC cells and 9L/F344 rats receiving 105 9LLUC cells at day 14. Compared with 9L/Wistar rats, the glioma in 9L/F344 rats continued to develop. The data are expressed as mean ± SEM and were analyzed with Student's t-test.
Mentions: 9LLUC glioma cells were injected into the cranium of Wistar or F344 rats to monitor tumor growth. Tumor growth was measured at the beginning on day 0 and weekly thereafter using bioluminescence imaging. By day 7, all animals showed successful tumor development following bioluminescence imaging. Tumor growth after intracranial injection of 9LLUC cells at varying doses into the right caudate nucleus of Wistar or F344 rats is shown in Figure 2. All 9LLUC/F344 rats yielded tumors with an injection of 105 cells (Figures 2A–D); in contrast, Wistar rats injected with 106 cells showed successful tumor development (Figures 2I-L), yet Wistar rats injected with 105 cells developed tumors only on day 7 and regressed thereafter (Figures 2E-H). Compared with 9L/Fischer rats, Wistar rats implanted with 9L glioma cells (106) showed a significant (P < 0.01) increase in photon counts at day 7, however, there was no difference in photon counts between 9L/Fischer rats and Wistar rats at day 21 (P > 0.05; Figure 3).

Bottom Line: Hematoxylin-eosin staining verified that intracranial tumors were gliomas.Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model.Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, the 263 Hospital, Beijing 101149, China ; Department of Neurology, South West Hospital, the Third Military Medical University of Chinese PLA, Chongqing 400038, China.

ABSTRACT
The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9L(LUC) glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9L(LUC)/F344 rats, and tumor regression was found in some 9L(LUC)/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

No MeSH data available.


Related in: MedlinePlus